Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mesoblast Limited ( (AU:MSB) ) has provided an announcement.
Mesoblast Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting their commitment to transparency and accountability in management and oversight. This release is significant as it reinforces Mesoblast’s dedication to maintaining high governance standards, potentially impacting investor confidence and stakeholder trust.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a company operating in the biotechnology industry, focusing on developing innovative cellular medicines. The company is involved in creating treatments for inflammatory diseases, cardiovascular diseases, and back pain, among other conditions.
YTD Price Performance: -17.10%
Average Trading Volume: 4,970,723
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.3B
For a thorough assessment of MSB stock, go to TipRanks’ Stock Analysis page.